Ionis Pharmaceuticals (IONS) News Today $32.33 -0.36 (-1.11%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$32.40 +0.07 (+0.23%) As of 02/21/2025 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D lifted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 22.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,206 shares of the company's stockFebruary 22 at 3:39 AM | marketbeat.comBMO Capital Markets Lowers Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00February 22 at 3:27 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $64.00 by Analysts at CitigroupCitigroup decreased their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday.February 21 at 1:54 PM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday.February 21 at 12:01 PM | marketbeat.comBMO Capital Markets Has Lowered Expectations for Ionis Pharmaceuticals (NASDAQ:IONS) Stock PriceBMO Capital Markets decreased their target price on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research report on Thursday.February 21 at 9:41 AM | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Ionis Pharmaceuticals (NASDAQ:IONS)Needham & Company LLC reissued a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday.February 21 at 8:09 AM | marketbeat.comIonis Pharmaceuticals price target lowered to $63 from $65 at BofAFebruary 21 at 5:58 AM | markets.businessinsider.comIonis Pharmaceuticals Reports Strong Financial Results for Q4 and Full Year 2024February 21 at 2:34 AM | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up After Earnings BeatFebruary 21 at 1:56 AM | americanbankingnews.comIonis Pharmaceuticals price target lowered to $60 from $61 at Raymond JamesFebruary 21 at 12:54 AM | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Earnings BeatIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up Following Better-Than-Expected EarningsFebruary 20 at 10:08 AM | marketbeat.comIonis Pharmaceuticals price target lowered to $64 from $67 at CitiFebruary 20 at 9:48 AM | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Posts Quarterly Earnings Results, Beats Estimates By $0.43 EPSIonis Pharmaceuticals (NASDAQ:IONS - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.43. Ionis Pharmaceuticals had a negative net margin of 44.58% and a negative return on equity of 88.98%. During the same quarter last year, the company earned $0.12 earnings per share.February 20 at 9:18 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Issues Earnings ResultsIonis Pharmaceuticals (NASDAQ:IONS - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.43. Ionis Pharmaceuticals had a negative return on equity of 88.98% and a negative net margin of 44.58%. During the same period last year, the company earned $0.12 earnings per share.February 20 at 8:59 AM | marketbeat.comIonis Pharmaceuticals trading halted, volatility trading pauseFebruary 19 at 4:35 PM | markets.businessinsider.comIonis posts Q4 beat as revenue base widensFebruary 19 at 4:35 PM | msn.comIonis Pharmaceuticals price target lowered to $38 from $45 at StifelFebruary 19 at 4:35 PM | markets.businessinsider.comIonis Pharmaceuticals, Inc. (IONS) Q4 2024 Earnings Call TranscriptFebruary 19 at 4:20 PM | seekingalpha.comIonis Pharmaceuticals Reports Strong Q4 Earnings After Recent FDA ApprovalFebruary 19 at 3:01 PM | seekingalpha.comIonis Pharma Beats Expectations for Q4February 19 at 1:26 PM | fool.comIonis Pharmaceuticals, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 19 at 12:20 PM | seekingalpha.comIonis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In JanuaryFebruary 18, 2025 | msn.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest UpdateIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 12,120,000 shares, an increase of 18.4% from the January 15th total of 10,240,000 shares. Based on an average daily trading volume, of 1,540,000 shares, the short-interest ratio is currently 7.9 days. Currently, 7.9% of the shares of the stock are sold short.February 16, 2025 | marketbeat.comSumitomo Mitsui Trust Group Inc. Lowers Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Sumitomo Mitsui Trust Group Inc. reduced its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 20.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 156,657February 14, 2025 | marketbeat.comIonis Pharma stock hits 52-week low at $30.86February 12, 2025 | msn.comIonis Pharmaceuticals (IONS) Expected to Announce Quarterly Earnings on WednesdayIonis Pharmaceuticals (NASDAQ:IONS) will be releasing earnings before the market opens on Wednesday, February 19, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=662836)February 12, 2025 | marketbeat.comWhy Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) RecentlyFebruary 11, 2025 | msn.comIonis Pharmaceuticals (NASDAQ:IONS) Sets New 52-Week Low - Time to Sell?Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 1-Year Low - What's Next?February 11, 2025 | marketbeat.comSovran Advisors LLC Invests $5.62 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Sovran Advisors LLC bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 171,812 shares of the company's stock, valued at approximately $5,617,000. IonFebruary 11, 2025 | marketbeat.comWhy Ionis Pharmaceuticals, Inc. (IONS) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comabrdn plc Has $14.03 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)abrdn plc raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 32.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 401,501 shares of the company's stock after purchasing an additional 98,227 shares during the period. abrdn pFebruary 8, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Patrick R. O'neil Sells 6,165 SharesFebruary 7, 2025 | insidertrades.comIonis Pharmaceuticals EVP sells $194,939 in stockFebruary 6, 2025 | msn.comIonis Pharmaceuticals CEO sells $1.23 million in stockFebruary 6, 2025 | msn.comPatrick R. O'neil Sells 6,165 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Patrick R. O'neil sold 6,165 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total value of $194,937.30. Following the completion of the sale, the executive vice president now directly owns 57,452 shares of the company's stock, valued at approximately $1,816,632.24. The trade was a 9.69 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.February 6, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells $1,229,380.95 in StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett P. Monia sold 38,843 shares of the business's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total transaction of $1,229,380.95. Following the completion of the sale, the chief executive officer now directly owns 180,683 shares in the company, valued at $5,718,616.95. This trade represents a 17.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.February 6, 2025 | marketbeat.comIonis to hold fourth quarter and full year 2024 financial results webcastFebruary 5, 2025 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by DAVENPORT & Co LLCDAVENPORT & Co LLC lowered its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 17.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,740 shares of the company's stockFebruary 5, 2025 | marketbeat.comIONS Stock Hits 52-Week Low at $31.24 Amidst Yearly DeclineFebruary 4, 2025 | msn.comEric Swayze Sells 1,367 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockFebruary 4, 2025 | insidertrades.comEric Swayze Sells 1,367 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Eric Swayze sold 1,367 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $32.31, for a total transaction of $44,167.77. Following the completion of the sale, the executive vice president now directly owns 48,017 shares in the company, valued at approximately $1,551,429.27. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.February 3, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) CFO Elizabeth L. Hougen Sells 1,523 SharesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CFO Elizabeth L. Hougen sold 1,523 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $32.44, for a total value of $49,406.12. Following the sale, the chief financial officer now owns 110,500 shares of the company's stock, valued at $3,584,620. The trade was a 1.36 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.February 3, 2025 | marketbeat.comInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells 13,242 Shares of StockIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) CEO Brett P. Monia sold 13,242 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $32.45, for a total transaction of $429,702.90. Following the completion of the transaction, the chief executive officer now owns 219,526 shares of the company's stock, valued at $7,123,618.70. This represents a 5.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.February 3, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Reaches New 12-Month Low - Here's WhyIonis Pharmaceuticals (NASDAQ:IONS) Reaches New 1-Year Low - Here's WhyFebruary 3, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have received an average rating of "Moderate Buy" from the nineteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five haveFebruary 2, 2025 | marketbeat.comIonis ‘remains confident in pelacarsen’ after Novartis update on Phase 3 timingFebruary 1, 2025 | markets.businessinsider.comNovartis delays Phase 3 readout for Ionis heart drugJanuary 31, 2025 | msn.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down - Time to Sell?Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down - Should You Sell?January 31, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by SG Americas Securities LLCSG Americas Securities LLC boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 222.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,927 shares of the company's stock after purJanuary 30, 2025 | marketbeat.comIonis Pharmaceuticals IncJanuary 29, 2025 | money.usnews.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.250.60▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼307▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UTHR News Today INCY News Today BMRN News Today NBIX News Today EXEL News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today ALKS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
